ArticleNature reviews. Drug discovery2011
Trial watch: Phase II failures: 2008-2010.
Article in Nature reviews. Drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02363647 (Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer), which is not on this map. Cited by 212 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
Who cites it
212 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation.Scientific reports · 2015Pooled it
- Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development--A Systematic Review.PloS one · 2015Pooled it
- The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial.European radiology · 2016Trial
- Recent Advances and Emerging Directions in Machine Learning-Based Breast Cancer Drug Discovery: A Comprehensive Review.Breast cancer (Dove Medical Press) · 2026Review
- Anti-Lung Cancer Agent Discovery and Development: A Review of Cross-Platform Correlation Across in silico, Network Pharmacology, in vitro, and in vivo Assessments.Drug design, development and therapy · 2026Review
- Characterisation of human in vitro tumour-associated macrophage models to define translational relevance.Scientific reports · 2025Article
- Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895.Cancer research communications · 2025Article
- A pan-cancer, pan-treatment model for predicting drug responses from patient-derived xenografts.NAR genomics and bioinformatics · 2025Article
- High-Quality In Vivo Chemical Probes for Protein Kinases Disclosed in 2024.ACS pharmacology & translational science · 2025Review
- MHNfs: Prompting In-Context Bioactivity Predictions for Low-Data Drug Discovery.Journal of chemical information and modeling · 2025Article
- Application of drug-induced growth rate inhibition and intracellular drug exposures for comprehensive evaluation of cellular drug sensitivity.Scientific reports · 2025Article
- Unveiling the Phenotypic Variability of Macrophages: Insights from Donor Diversity and Pooling Strategies.International journal of molecular sciences · 2025Article
- Gossypol is a natural product with good antimalarial activity against Plasmodium falciparum clinical isolates.Scientific reports · 2025Article
- Comparison of Malondialdehyde, Acetylcholinesterase, and Apoptosis-Related Markers in the Cortex and Hippocampus of Cognitively Dysfunctional Mice Induced by Scopolamine.Biomedicines · 2024Article
- Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition.Nature reviews. Drug discovery · 2024Review
- A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia.Advances in therapy · 2024Article
- Chromatin Remodeling in Patient-Derived Colorectal Cancer Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- PET Imaging of Peptide Probe Al[Molecular pharmaceutics · 2024Article
- Predicting drug-target binding affinity with cross-scale graph contrastive learning.Briefings in bioinformatics · 2023Article
- Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor.Cell chemical biology · 2023Article
152 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
21532551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.